Anaelle Cassemiche, Sarah Schoffit, Mathieu Manassero, Matthias Kohlhauer
{"title":"Comparison of grapiprant and meloxicam for management of postoperative joint pain in dogs: A randomized, double-blinded, prospective clinical trial","authors":"Anaelle Cassemiche, Sarah Schoffit, Mathieu Manassero, Matthias Kohlhauer","doi":"10.1111/jvim.17136","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Grapiprant is a novel anti-inflammatory drug approved for the treatment of pain associated with osteoarthritis in dogs.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>Compare the efficacy of grapiprant vs meloxicam for the management of postoperative joint pain in dogs.</p>\n </section>\n \n <section>\n \n <h3> Animals</h3>\n \n <p>Forty-eight dogs presented with cranial cruciate ligament disease and treated by tibial plateau leveling osteotomy (TPLO) between May 2020 and May 2022.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this randomized, double blinded, prospective clinical trial, client-owned dogs with naturally occurring unilateral cruciate ligament rupture were enrolled on the day of surgery. The day after surgery, all animals received a subcutaneous injection of 0.2 mg/kg of meloxicam and were randomly assigned to receive either oral grapiprant (2 mg/kg) or meloxicam (0.1 mg/kg), once a day for 14 days, in a blinded manner. The primary endpoint of the study was the pain severity (PSS) and interference (PIS) scores, assessed by the Canine Brief Pain Inventory (CBPI) at day 3, 7, 10 and 15 after the surgery.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Three days after surgery, grapiprant treated dogs had lower PSS compared to meloxicam treated dogs with a mean ± SD of 2.76 ± 0.18 vs 3.25 ± 0.23, respectively (difference of −0.49 [95% CI −0.94 to −0.04], <i>P</i> = .032). Pain Interference Score was also lower in grapiprant group at day 3 (4.11 ± 0.18 vs 4.69 ± 0.16 in meloxicam group [difference of −0.58 {95% CI −1.03 to −0.13}, <i>P</i> = .013]) and at day 10 (2.23 ± 0.13 vs 2.72 ± 0.28 [difference of −0.49 {95% CI −0.92 to −0.01}, <i>P</i> = .049]).</p>\n </section>\n \n <section>\n \n <h3> Conclusions and Clinical Importance</h3>\n \n <p>Our study supports the use of grapiprant as an alternative analgesic to meloxicam for management of postoperative joint pain in dogs.</p>\n </section>\n </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"38 4","pages":"2324-2332"},"PeriodicalIF":2.1000,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11256200/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvim.17136","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Grapiprant is a novel anti-inflammatory drug approved for the treatment of pain associated with osteoarthritis in dogs.
Objective
Compare the efficacy of grapiprant vs meloxicam for the management of postoperative joint pain in dogs.
Animals
Forty-eight dogs presented with cranial cruciate ligament disease and treated by tibial plateau leveling osteotomy (TPLO) between May 2020 and May 2022.
Methods
In this randomized, double blinded, prospective clinical trial, client-owned dogs with naturally occurring unilateral cruciate ligament rupture were enrolled on the day of surgery. The day after surgery, all animals received a subcutaneous injection of 0.2 mg/kg of meloxicam and were randomly assigned to receive either oral grapiprant (2 mg/kg) or meloxicam (0.1 mg/kg), once a day for 14 days, in a blinded manner. The primary endpoint of the study was the pain severity (PSS) and interference (PIS) scores, assessed by the Canine Brief Pain Inventory (CBPI) at day 3, 7, 10 and 15 after the surgery.
Results
Three days after surgery, grapiprant treated dogs had lower PSS compared to meloxicam treated dogs with a mean ± SD of 2.76 ± 0.18 vs 3.25 ± 0.23, respectively (difference of −0.49 [95% CI −0.94 to −0.04], P = .032). Pain Interference Score was also lower in grapiprant group at day 3 (4.11 ± 0.18 vs 4.69 ± 0.16 in meloxicam group [difference of −0.58 {95% CI −1.03 to −0.13}, P = .013]) and at day 10 (2.23 ± 0.13 vs 2.72 ± 0.28 [difference of −0.49 {95% CI −0.92 to −0.01}, P = .049]).
Conclusions and Clinical Importance
Our study supports the use of grapiprant as an alternative analgesic to meloxicam for management of postoperative joint pain in dogs.
背景：Grapiprant 是一种新型抗炎药物，已被批准用于治疗犬骨关节炎相关疼痛：格拉吡群是一种新型抗炎药物，已被批准用于治疗犬骨关节炎引起的疼痛：比较格拉吡群与美洛昔康治疗犬关节术后疼痛的疗效：方法：在2020年5月至2022年5月期间，对48只患有颅交叉韧带疾病的狗进行胫骨平台平整截骨术（TPLO）治疗：在这项随机、双盲、前瞻性临床试验中，客户饲养的患有自然发生的单侧十字韧带断裂的狗在手术当天入组。手术后第二天，所有动物都接受了0.2毫克/千克美洛昔康的皮下注射，并随机分配接受口服格拉吡坦（2毫克/千克）或美洛昔康（0.1毫克/千克），每天一次，连续14天。研究的主要终点是犬简易疼痛量表（CBPI）评估的术后第3、7、10和15天的疼痛严重程度（PSS）和干扰程度（PIS）评分：与美洛昔康治疗的犬相比，格拉吡群治疗的犬在术后三天的PSS较低，平均值（± SD）分别为2.76 ± 0.18 vs 3.25 ± 0.23（差异为-0.49 [95% CI -0.94 to -0.04]，P = .032）。格拉潘组在第3天（4.11 ± 0.18 vs 4.69 ± 0.16美洛昔康组[差异为-0.58 {95% CI -1.03 to -0.13}，P = .013]）和第10天（2.23 ± 0.13 vs 2.72 ± 0.28[差异为-0.49 {95% CI -0.92 to -0.01}，P = .049]）的疼痛干扰评分也较低：我们的研究支持使用格拉吡群作为美洛昔康的替代镇痛药来治疗狗的术后关节疼痛。
期刊介绍：
The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
